The prevalence of hypertrophic cardiomyopathy is approgimately 0.2 % whereby the obstructive form accounts for one quarter. The basic treatment involves administration of negatively inotropic drugs (beta-blockers and/or verapamil), which reduce the intraventricular pressure gradient and have a positive impact on the symptomatology. In patients refractory or intolerant to medicamentous treatment surgical or catheterization is used. Percutaneous transluminal Septal myocardial ablation reduces significantly the symptomatology of dyspncea and stenocardia, increases load tolerance and improves the left ventricular diastolic function. In none of the mentioned therapeutic aproaches so far a favourable effect on the prognosis of patients with a risk profile associated with hypertrophic obstructivel cardiomyopathy was proved.

        Key words: Hypertrophic cardiomyopathy - Obstruction - Beta-blockers - Verapamil - Percutaneous transluminal Septal myocardial ablation